Logo

Biocept: Samuel Riccitelli

Oct 23, 2020

Biocept has appointed Samuel Riccitelli to its board of directors, effective immediately, and ahead of the planned retirement of Bruce Huebner, who will leave the board on Nov. 30, 2020. Riccitelli boasts 35 years of experience in the molecular diagnostics industry, having served in executive-level positions and on the boards of multiple publicly traded companies. At Biocept, he will initially serve on the audit committee and the science and technology committee.

Riccitelli currently serves as an independent consultant to healthcare companies and is a director of OrthoPediatrics, a company focused on the orthopedic implant needs of children. Prior to that he was CEO of Pathnostics, a molecular diagnostics company focused on improving antibiotic stewardship. He also served as chairman of Precipio; president, CEO, and director of Signal Genetics; and executive VP and chief operating officer of Genoptix. Riccitelli received a BA from Washington and Jefferson College and an MS in engineering from The University of Texas.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.